Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Stomach Neoplasms 8Colorectal Neoplasms 7Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Melanoma 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Sarcoma 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Anus Neoplasms 2Wilms Tumor 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

pembrolizumab 12Nivolumab 6Cyclophosphamide 6fludarabine 5Ipilimumab 4amatuximab 3Cisplatin 3tislelizumab 2spartalizumab 2fludarabine phosphate 2budigalimab 2belinostat 2Plicamycin 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Cytoreduction Surgical Procedures 2venetoclax 1tocilizumab 1talazoparib 1sotorasib 1rovalpituzumab tesirine 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1irinotecan sucrosofate 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma × fludarabine phosphate × Gastrointestinal × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡